Skip to content

Comparison of Raltitrexed-Eluting beads vs Doxorubicin-eluting beads to Improve clinical outcome for the Treatment of?Intermediate and Late Primary Hepatocellular Carcinoma

Comparison of Raltitrexed-Eluting beads vs Doxorubicin-eluting beads to Improve clinical outcome for the Treatment of?Intermediate and Late Primary Hepatocellular Carcinoma

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036312
Enrollment
Unknown
Registered
2020-08-22
Start date
2020-08-30
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Sponsors

The Fourth Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years old, male and female; 2. The clinical diagnosis was primary liver cancer; 3. The child Pugh liver function grade was a or B; 4. ECOG PS 0-1; 5. BCLC stage B, C; 6. There was no serious organic disease of heart, lung and brain; 7. There was no history of other malignant tumors; 8. The expected survival time was more than 3 months; 9. The patient or legal representative has been informed of the nature of the study and understanding of the protocol will ensure compliance.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. He had a history of organ transplantation; 3. Portal vein tumor thrombus was found; 4. Combined with distant metastasis; 5. Active bleeding caused by various reasons; 6. Severe acute or chronic diseases or infectious diseases; 7. Those who have been treated with liver cancer ablation or iodine particles.

Design outcomes

Primary

MeasureTime frame
progress free survival;

Countries

China

Contacts

Public ContactLi Zhigang

the Fourth Hospital of Hebei Medical University

Fsklizhigang2013@163.com+86 13831162068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026